PDF(Pubmed)
Abstract：
UNASSIGNED: In 2022, the United States experienced a national shortage of infant formula due to a global supply chain crisis and a large-scale domestic formula recall. The existing literature on healthcare providers\' (HCPs) clinical decision-making during formula shortages is limited. This study aims to analyze the factors influencing pediatric HCP clinical decision-making when switching between amino acid formulas (AAF) for managing cow\'s milk protein allergy (CMPA) in infants under 24 months of age during an unprecedented national formula shortage.
UNASSIGNED: The study included pediatric HCPs with experience managing CMPA in infants and toddlers under 24 months during the formula shortage from January 2022 to November 2022. A de-identified survey comprising 26 questions examining driving factors used in clinical decision-making was administered to pediatric HCPs using a real-time mobile data collection tool.
UNASSIGNED: Among the surveyed pediatric HCPs (n = 75), the factors most frequently considered as \"extremely important\" when switching to another AAF included safety (85%), tolerability (73%), and efficacy (83%). No statistically significant differences were found in HCP ratings among the listed examined factors of the four AAFs. The availability of specific formulas was the only factor that exhibited a statistically significant difference in perceived performance among pediatric HCPs when comparing the four AAFs (p < 0.05).
UNASSIGNED: This study elucidates the crucial aspects that influenced pediatric HCPs\' selection of AAFs for CMPA management during the 2022 formula shortage. The findings highlight the significance of safety, tolerability, efficacy, and availability in the pediatric HCP decision-making processes.
UNASSIGNED: The study included pediatric HCPs with experience managing CMPA in infants and toddlers under 24 months during the formula shortage from January 2022 to November 2022. A de-identified survey comprising 26 questions examining driving factors used in clinical decision-making was administered to pediatric HCPs using a real-time mobile data collection tool.
UNASSIGNED: Among the surveyed pediatric HCPs (n = 75), the factors most frequently considered as \"extremely important\" when switching to another AAF included safety (85%), tolerability (73%), and efficacy (83%). No statistically significant differences were found in HCP ratings among the listed examined factors of the four AAFs. The availability of specific formulas was the only factor that exhibited a statistically significant difference in perceived performance among pediatric HCPs when comparing the four AAFs (p < 0.05).
UNASSIGNED: This study elucidates the crucial aspects that influenced pediatric HCPs\' selection of AAFs for CMPA management during the 2022 formula shortage. The findings highlight the significance of safety, tolerability, efficacy, and availability in the pediatric HCP decision-making processes.
摘要：
■2022年，由于全球供应链危机和大规模的国内配方奶粉召回，美国经历了全国婴儿配方奶粉短缺。关于配方短缺期间医疗保健提供者(HCP)临床决策的现有文献是有限的。本研究旨在分析在前所未有的国家配方奶粉短缺期间，在24个月以下婴儿管理牛乳蛋白过敏（CMPA）的氨基酸配方（AAF）之间切换时，影响儿科HCP临床决策的因素。
■该研究包括儿科HCP，在2022年1月至2022年11月的配方奶粉短缺期间，在24个月以下的婴幼儿中管理CMPA的经验。使用实时移动数据收集工具对儿科HCP进行了一项包括26个问题的去识别调查，这些问题检查了临床决策中使用的驱动因素。
■在接受调查的儿科HCP（n=75）中，切换到另一个AAF时，最常被认为是“极其重要”的因素包括安全性(85%)，耐受性（73%），和疗效(83%)。在列出的四个AAF的检查因子中，HCP评级没有发现统计学上的显着差异。当比较四种AAF时，特定配方的可用性是在儿科HCP中表现出统计学上显着差异的唯一因素（p<0.05）。
■这项研究阐明了在2022年配方短缺期间影响儿科HCP选择用于CMPA管理的AAF的关键方面。这些发现强调了安全的重要性，耐受性,功效,以及儿科HCP决策过程中的可用性。
■该研究包括儿科HCP，在2022年1月至2022年11月的配方奶粉短缺期间，在24个月以下的婴幼儿中管理CMPA的经验。使用实时移动数据收集工具对儿科HCP进行了一项包括26个问题的去识别调查，这些问题检查了临床决策中使用的驱动因素。
■在接受调查的儿科HCP（n=75）中，切换到另一个AAF时，最常被认为是“极其重要”的因素包括安全性(85%)，耐受性（73%），和疗效(83%)。在列出的四个AAF的检查因子中，HCP评级没有发现统计学上的显着差异。当比较四种AAF时，特定配方的可用性是在儿科HCP中表现出统计学上显着差异的唯一因素（p<0.05）。
■这项研究阐明了在2022年配方短缺期间影响儿科HCP选择用于CMPA管理的AAF的关键方面。这些发现强调了安全的重要性，耐受性,功效,以及儿科HCP决策过程中的可用性。
